REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt
A chronology of Replimune's RP1 regulatory disclosures alleges that between October 20, 2025 and April 10, 2026, investors were told the FDA resubmission was on track while previously communicated study-design concerns allegedly remained unresolved. NEW YORK, Sept. 17, 2026 /PRNewswire/...